Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Ischemic Stroke

ClinicalTrials.gov lists 2,570 trials for Ischemic Stroke or a narrower condition beneath it. Penumbra Inc. has the most among industry and government lead sponsors, with 14.

MeSH D000083242 Nervous System Diseases C10 C14
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 94 Phase 1/2 Phase 1/2 51 Phase 2 Phase 2 254 Phase 2/3 Phase 2/3 64 Phase 3 Phase 3 257 Phase 4 Phase 4 150 Not applicable Not applicable 923 Observational Observational 774 Phase 1 Phase 1 94 Phase 1/2 Phase 1/2 51 Phase 2 Phase 2 254 Phase 2/3 Phase 2/3 64 Phase 3 Phase 3 257 Phase 4 Phase 4 150 Not applicable Not applicable 923 Observational Observational 774

Trials per phase

1 more section with rows

2,533 of the 2,570 trials are tagged with Ischemic Stroke itself; the rest are tagged with a narrower condition beneath it.

Get the Ischemic Stroke report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Ischemic Stroke trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 7 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 257

1990: 1 trials (Observational 1) 1993: 3 trials (Observational 2, Phase 4 1) 1997: 2 trials (Observational 2) 1998: 1 trials (Observational 1) 1999: 1 trials (Observational 1) 2000: 7 trials (Observational 3, Phase 3 1, Phase 2 3) 2001: 6 trials (Observational 3, Phase 4 1, Phase 2 2) 2002: 2 trials (Observational 1, Phase 2/3 1) 2003: 17 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 3 2, Phase 2 3, Phase 1/2 3) 2004: 17 trials (Not applicable 2, Phase 4 4, Phase 3 5, Phase 2 5, Phase 1 1) 2005: 18 trials (Observational 2, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1/2 2, Phase 1 3) 2006: 17 trials (Observational 3, Not applicable 1, Phase 4 2, Phase 3 5, Phase 2 4, Phase 1/2 1, Phase 1 1) 2007: 24 trials (Observational 9, Not applicable 4, Phase 4 1, Phase 3 1, Phase 2/3 2, Phase 2 4, Phase 1 3) 2008: 22 trials (Observational 8, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2/3 2, Phase 2 6, Phase 1 1) 2009: 41 trials (Observational 10, Not applicable 12, Phase 4 5, Phase 3 3, Phase 2 6, Phase 1/2 2, Phase 1 3) 2010: 40 trials (Observational 13, Not applicable 11, Phase 4 4, Phase 3 2, Phase 2/3 1, Phase 2 4, Phase 1/2 2, Phase 1 3) 2011: 47 trials (Observational 20, Not applicable 7, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 6, Phase 1/2 6, Phase 1 4) 2012: 69 trials (Observational 21, Not applicable 9, Phase 4 5, Phase 3 12, Phase 2 10, Phase 1/2 3, Phase 1 9) 2013: 72 trials (Observational 19, Not applicable 23, Phase 4 5, Phase 3 6, Phase 2/3 2, Phase 2 12, Phase 1 5) 2014: 74 trials (Observational 29, Not applicable 17, Phase 4 6, Phase 3 7, Phase 2/3 4, Phase 2 9, Phase 1 2) 2015: 77 trials (Observational 31, Not applicable 23, Phase 4 7, Phase 3 5, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 4) 2016: 100 trials (Observational 38, Not applicable 27, Phase 4 6, Phase 3 4, Phase 2 19, Phase 1/2 2, Phase 1 4) 2017: 96 trials (Observational 38, Not applicable 33, Phase 4 4, Phase 3 5, Phase 2/3 3, Phase 2 7, Phase 1/2 1, Phase 1 5) 2018: 127 trials (Observational 44, Not applicable 50, Phase 4 7, Phase 3 14, Phase 2/3 2, Phase 2 6, Phase 1/2 1, Phase 1 3) 2019: 143 trials (Observational 51, Not applicable 64, Phase 4 6, Phase 3 7, Phase 2 9, Phase 1/2 3, Phase 1 3) 2020: 136 trials (Observational 54, Not applicable 54, Phase 4 6, Phase 3 8, Phase 2/3 3, Phase 2 4, Phase 1/2 4, Phase 1 3) 2021: 190 trials (Observational 73, Not applicable 66, Phase 4 7, Phase 3 10, Phase 2/3 6, Phase 2 18, Phase 1/2 4, Phase 1 6) 2022: 217 trials (Observational 64, Not applicable 89, Phase 4 13, Phase 3 23, Phase 2/3 2, Phase 2 21, Phase 1/2 2, Phase 1 3) 2023: 232 trials (Observational 59, Not applicable 98, Phase 4 14, Phase 3 20, Phase 2/3 9, Phase 2 23, Phase 1/2 2, Phase 1 7) 2024: 256 trials (Observational 62, Not applicable 118, Phase 4 11, Phase 3 33, Phase 2/3 8, Phase 2 15, Phase 1/2 2, Phase 1 7) 2025: 257 trials (Observational 45, Not applicable 113, Phase 4 12, Phase 3 41, Phase 2/3 8, Phase 2 25, Phase 1/2 6, Phase 1 7)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 247
2025 257
2024 256
2023 232
2022 217
2021 190
2020 136
2019 143
2018 127
2017 96

Showing 10 of 32 earlier years.

Start your 14-day trial Email me all 32 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 290 trials starting in 2026 and about 270 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 380 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 1,167 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Ischemic Stroke trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 94
Phase 1/2 51
Phase 2 254
Phase 2/3 64
Phase 3 257
Phase 4 150
Not applicable 923
Observational 774
Expanded access 3

How many Ischemic Stroke trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 236
Recruiting 533
Enrolling by invitation 21
Active, not recruiting 70
Available 1

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Ischemic Stroke trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Penumbra Inc. 14

Which drugs are being tested for Ischemic Stroke? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Tenecteplase 58
TIROFIBAN 20
Cilostazol 17
Cerebrolysin 14

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
EC Aspirin 58
Clopidogrel 75 38
Alteplase t-PA 36
Mechanical thrombectomy 25
Standard Medical Treatment 20

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Ischemic Stroke trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
SAE 660 1
Pneumonia 632 48
Atrial fibrillation 466 29
Death 354 32
Hospitalization 341 4

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Ischemic Stroke? (1,114)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial. BMJ (Clinical research ed.) 2026 Yes
Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study. Stroke 2026 Yes
Antihypertensive Treatments After Acute Ischemic Stroke: to Continue or Not? Hypertension (Dallas, Tex. : 1979) 2026 Yes
Functional Outcomes of Human Urinary Kallindinogenases in Treatment of Acute Ischemic Stroke. Stroke 2026 Yes
Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke. Circulation 2026 Yes

Showing 5 of 1,114 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages